Tetra Bio-Pharma Inc. TBPMQ
OTC PK
| 08/31/2022 | 05/31/2022 | 02/28/2022 | 11/30/2021 | 08/31/2021 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -56.78% | -- | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -61.68% | -- | -- | -- | -- |
| Operating Income | 61.68% | -- | -- | -- | -- |
| Income Before Tax | -33.97% | -- | -- | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -33.97% | -- | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.55% | -- | -- | -- | -- |
| EBIT | 61.68% | -- | -- | -- | -- |
| EBITDA | 61.93% | -- | -- | -- | -- |
| EPS Basic | 7.74% | -- | -- | -- | -- |
| Normalized Basic EPS | 63.88% | -- | -- | -- | -- |
| EPS Diluted | 7.74% | -- | -- | -- | -- |
| Normalized Diluted EPS | 63.88% | -- | -- | -- | -- |
| Average Basic Shares Outstanding | 23.60% | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | 23.60% | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |